92 / 400
MONDAY
TUESDAY
WEDNESDAY
THURSDAY
84
SCIENTIFIC PROGRAMME
OS-04
Oral Presentation Session
08:15–09:45
|
Room R13
TOPIC 17:
Psychotherapy
Psychotherapeutical interventions I
Chairs:
Daniel Nahum, USA
Michael Linden, Germany
001
Impact of therapist change after initial contact
and traumatic burden on dropout in a naturalistic
sample of inpatients with borderline pathology
receiving dialectical behavior therapy
Carolin Steuwe, Germany
Michaela Berg, Martin Driessen, Thomas Beblo
002
Development and preliminary evaluation of
manual-based group intensive outpatient program
(M-IOP) for patients with bipolar disorders in China
Xia Sun, People's Republic of China
Chengmei Yuan, Yiru Fang, Chenyu Ye, Yu Wang,
Yong Wang, Jia Huang, Rui Song, Lili Xue, Weihong Lu,
Zhiguo Wu, Danping Wu
003
PTSD symptom profiles and NET treatment for
refugee children and adolescents resettled in Canada:
results from a randomized controlled trial
Anne Mantini, Canada
Morton Beiser, Vasanthi Srinivasan, Patricia O'Campo
004
Exposure therapy for obsessive-compulsive
disorder – rethinking the theory / insights from
inhibitory learning theory
Christian Stierle, Germany
005
Treatment of patients with fear of driving
following a traffic accident by a virtual reality expo-
sure therapy in a driving simulator – a pilot study
funded by the DGUV (FR232)
Yvonne Kaussner, Germany
Stefanie Schoch, Ramona Baur, Sonja Hoffmann,
Petra Markel, Anna Kuraszkiewicz, Paul Pauli
OS-05
Oral Presentation Session
08:15–09:45
|
Room Lindau 5
TOPIC 3:
Psychotic disorders
Psychotic disorders I
Chairs:
Christoph Correll, USA
Alkomiet Hasan, Germany
001
Modified cognitive behavioral therapy for
elderly patients with schizophrenia – a randomized,
controlled pilot trial
Bernhard W. Müller, Germany
Christian Kärgel, Magdalena Horacek, Ute Darrelmann,
Imma Fischer, Anja Heger, Daniela Kariofillis, Beate
Nentwich, Christoph Meisner, Claudia Ose, Svenja
Unsöld, Jens Wiltfang, Michael Wagner, Stefan
Klingberg, Gudrun Sartory
002
Antipsychotic augmentation vs. monotherapy
in schizophrenia: systematic review, meta-analysis
and metaregression analysis
Britta Galling, Germany
Christoph Correll
003
Adjuvant Aspirin therapy in schizophrenia:
randomized, placebo controlled trial
Amina Aissa, Tunisia
Arij Ben Chaabene, Amine Larnaout, Kaouther Ben
Neticha, Ben Ammar Hanene, Emira Khelifa, Fayza Ayari,
Ryad Tamouza, Fethi Guemira, Zouhaier El Hechmi
004
Vitamin D and schizophrenia: state of the art
Lígia Castanheira, Portugal
Carla Ferreira, Liliana Ferreira, João Miguel Pereira
005
Efficacy and safety of MIN-101: a new drug for
the treatment of negative symptoms in schizophrenia
– a 12-week randomized, double blind, placebo-
controlled trial
Michael Davidson, Israel
Remy Luthringer, Jay Saoud, Corinne Staner
006
Predictors of non-adherence to medication
among patients with schizophrenia
Babatunde Fadipe, Nigeria
Timothy Adebowale, Andrew Olagunju, Adegboyega
Ogunwale
OS-06
Oral Presentation Session
08:15–09:45
|
Room R6
TOPIC 23:
Health care research and models, health care
policy
Health care models and services I
Chairs:
Virginia Rosabal, Costa Rica
Georg Schomerus, Germany
001
How does utilization of health care services
change in people with dementia served by Dementia
Care Networks in Germany? Results of the DemNet-
D-study
René Thyrian, Germany
Bernhard Michalowsky, Johannes Hertel, Markus
Wübbeler, Bernhard Holle, Susanne Schäfer-Walkmann,
Karin Wolf-Ostermann, Wolfgang Hoffmann
002
Lessons learned from implementing a delir
pathway in the preoperative setting – or what we
think we could learn
Jutta Ernst, Switzerland
003
Remembrance of things present
Peter Maeck, USA
004
Achieving a high ratio of crisis resolution home
treatment care to inpatient care in London using an
integrated adult acute care pathway
Bill Travers, United Kingdom
Tracy Barry, Asif Bachlani, Wellington Makala